Insider Buying: Perspective Therapeutics (NYSEAMERICAN:CATX) Director Buys 15,000 Shares of Company Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Frank Morich bought 15,000 shares of the stock in a transaction on Monday, November 16th. The stock was acquired at an average cost of $0.94 per share, for a total transaction of $14,100.00. Following the acquisition, the director directly owned 30,000 shares in the company, valued at approximately $28,200. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Frank Morich also recently made the following trade(s):

  • On Thursday, November 12th, Frank Morich purchased 15,000 shares of Perspective Therapeutics stock. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $15,000.00.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $0.92 on Tuesday. The company has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $3.43. The company has a quick ratio of 6.61, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 52 week low of $0.78 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. On average, equities research analysts forecast that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Bank of America reduced their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Friday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. William Blair initiated coverage on Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating on the stock. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. Finally, BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.10.

Read Our Latest Analysis on CATX

Key Headlines Impacting Perspective Therapeutics

Here are a few of the latest headlines about CATX:

  • Positive Sentiment: Several company insiders bought shares in open-market transactions on November 12. Purchases included 35,000 shares by Markus Puhlmann, 23,750 by director Lori Woods, and 24,898 by director Robert Williamson across two reported transactions. Director Frank Morich also bought 15,000 shares that day, then acquired another 15,000 shares on November 16 at an average of $0.94. The buying may signal insiders’ confidence, though it does not guarantee a recovery. Insider buying report Morich SEC filing
  • Neutral Sentiment: Analyst opinion remains broadly favorable, with nine Buy ratings and two Holds cited, but target cuts show increased caution: Wedbush lowered its target to $7 from $9, while Piper Sandler reduced its target to $14 from $16. Analyst ratings and estimates
  • Negative Sentiment: Perspective Therapeutics’ latest quarter fell short of forecasts: its loss was $0.27 per share versus the $0.24 expected, and revenue was $0.02 million versus $0.06 million expected. The stock is also far below its 50-day and 200-day moving averages and near its 12-month low, reflecting substantial recent weakness. CATX earnings information

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth $26,424,000. Affinity Asset Advisors LLC grew its position in Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after acquiring an additional 2,864,582 shares during the last quarter. Avidity Partners Management LP grew its position in Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares during the last quarter. Spruce Street Capital LP acquired a new position in Perspective Therapeutics during the first quarter worth about $10,955,000. Finally, Marshall Wace LLP acquired a new position in Perspective Therapeutics during the third quarter worth about $4,075,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Featured Articles

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.